Copyright © Inderes 2011 - present. All rights reserved.
Log in to receive notifications.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Biosergen

0.3

 

SEK

 

+2.39 %

Less than 1K followers

BIOSGN

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus
+2.39%
-29.91%
-46.81%
-43.4%
-29.58%
-21.67%
-91.3%
-
-91.88%

Biosergen is a biotechnology company. The company specializes in the research and development of various pharmaceuticals. The product portfolio includes, for example, the company's product BSG005, a fungicidal pharmaceutical in the clinical phase. In addition to the main business, service and associated ancillary services are also offered. The company operates in Norway. Biosergen was founded in 2004 and is headquartered in Solna.

Read more
Market cap
70.45M SEK
Turnover
320.27K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
21/5
2025

Interim report Q1'25

11/6
2025

General meeting '25

20/8
2025

Interim report Q2'25

All
Press releases
3rd party
ShowingAll content types
Press release3/7/2025, 2:44 PM

Carlsquare: Research update Biosergen: Continued success in India and cash injection

Biosergen
Press release3/7/2025, 10:15 AM

Biosergen AB: BioStock: Biosergen skalar upp för framtida framgångar

Biosergen
Press release3/7/2025, 10:15 AM

Biosergen AB: BioStock: Biosergen scales up for future wins

Biosergen

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release3/5/2025, 7:30 AM

Biosergen AB: Biosergen publicerar delårsrapport för fjärde kvartalet 2024

Biosergen
Regulatory press release3/5/2025, 7:30 AM

Biosergen AB: Biosergen publishes interim report for fourth quarter 2024

Biosergen
Press release2/11/2025, 11:25 AM

Carlsquare: Carlsquare Equity Research interview with Biosergen

Biosergen
Press release2/7/2025, 7:36 AM

Biosergen AB: BioStock: Biosergen's CEO: "These findings open up new possibilities"

Biosergen
Press release2/7/2025, 7:36 AM

Biosergen AB: BioStock: Biosergens vd: "These findings open up new possibilities"

Biosergen
Regulatory press release2/4/2025, 9:44 AM

Biosergen AB: Biosergen Successfully Completes Second Cohort of BSG005 Clinical Trial, Gaining Conclusive Proof-of-Concept Data, and Confirms 2025 Objectives

Biosergen
Regulatory press release2/4/2025, 9:44 AM

Biosergen AB: Biosergen slutför den andra kohorten i den kliniska studien BSG005 framgångsrikt, erhåller konklusiva proof-of-concept-data och bekräftar målen för 2025

Biosergen
Regulatory press release12/20/2024, 12:40 PM

Biosergen AB: Biosergen Agrees to Accelerated Dosing Escalation in Ongoing Second Cohort of Clinical Trial

Biosergen
Regulatory press release12/20/2024, 12:40 PM

Biosergen AB: Biosergen samtycker till accelererad dosökning i den pågående andra kohorten i den kliniska prövningen

Biosergen
Regulatory press release12/5/2024, 10:29 AM

Biosergen AB: Biosergen resolves on a compensation issue to underwriters in connection with the completed exercise period for warrants of series TO3

Biosergen
Regulatory press release12/5/2024, 10:29 AM

Biosergen AB: Biosergen beslutar om ersättningsemissions till garanter i samband med att nyttjandeperioden för teckningsoptioner av serie TO3 löpt ut

Biosergen
Regulatory press release12/3/2024, 7:22 PM

Biosergen AB conducts a directed share issue to underwriters in connection with the completed exercise period for warrants of series TO3

Biosergen
Regulatory press release12/3/2024, 7:19 PM

Biosergen AB tillförs cirka 44,9 MSEK genom teckningsoptioner av serie TO3

Biosergen
Regulatory press release12/3/2024, 7:19 PM

Biosergen AB receives approximately SEK 44.9 million through warrants of series TO3

Biosergen
Regulatory press release11/26/2024, 10:57 AM

Biosergen AB: Biosergen doserar de första patienterna i den andra kohorten i den kliniska studien BSG005 för behandling av livshotande svampinfektioner

Biosergen
Regulatory press release11/26/2024, 10:57 AM

Biosergen AB: Biosergen Doses First Patients in Second Cohort of BSG005 Clinical Trial for Life-Threatening Fungal Infections

Biosergen
Regulatory press release11/26/2024, 10:01 AM

Sista dag för handel med teckningsoptionerna av serie TO3 i Biosergen AB är idag, den 26 november 2024

Biosergen
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Privacy preferences

Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.